Replimune Group (REPL) Competitors

Replimune Group (NASDAQ:REPL) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, community ranking, media sentiment and profitability.

Which has more volatility and risk, REPL or VKTX?

Replimune Group has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Does the MarketBeat Community prefer REPL or VKTX?

Viking Therapeutics received 465 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 80.08% of users gave Viking Therapeutics an outperform vote while only 63.91% of users gave Replimune Group an outperform vote.

Company	Underperform	Outperform
Replimune Group	Outperform Votes 170 63.91%	Underperform Votes 96 36.09%
Viking Therapeutics	Outperform Votes 635 80.08%	Underperform Votes 158 19.92%

Is REPL or VKTX more profitable?

Viking Therapeutics' return on equity of -11.93% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-54.84%	-42.97%
Viking Therapeutics	N/A	-11.93%	-11.57%

Does the media prefer REPL or VKTX?

In the previous week, Viking Therapeutics had 15 more articles in the media than Replimune Group. MarketBeat recorded 17 mentions for Viking Therapeutics and 2 mentions for Replimune Group. Replimune Group's average media sentiment score of 1.29 beat Viking Therapeutics' score of 0.94 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate REPL or VKTX?

Replimune Group currently has a consensus target price of $20.83, indicating a potential upside of 113.02%. Viking Therapeutics has a consensus target price of $87.15, indicating a potential upside of 201.05%. Given Viking Therapeutics' higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Viking Therapeutics	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Which has preferable earnings and valuation, REPL or VKTX?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$215.79M	-$3.07	-3.19
Viking Therapeutics	N/A	N/A	-$109.96M	-$1.15	-25.17

Do insiders & institutionals have more ownership in REPL or VKTX?

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Viking Therapeutics beats Replimune Group on 11 of the 16 factors compared between the two stocks.